180 related articles for article (PubMed ID: 25833214)
21. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
22. Cocktails for cancer with a measure of immunotherapy.
Ledford H
Nature; 2016 Apr; 532(7598):162-4. PubMed ID: 27075078
[No Abstract] [Full Text] [Related]
23. Immune check-point in cervical cancer.
De Felice F; Marchetti C; Palaia I; Ostuni R; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Sep; 129():40-43. PubMed ID: 30097236
[TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.
Berghoff AS; Venur VA; Preusser M; Ahluwalia MS
Am Soc Clin Oncol Educ Book; 2016; 35():e116-22. PubMed ID: 27249713
[TBL] [Abstract][Full Text] [Related]
25. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Benci JL; Xu B; Qiu Y; Wu TJ; Dada H; Twyman-Saint Victor C; Cucolo L; Lee DSM; Pauken KE; Huang AC; Gangadhar TC; Amaravadi RK; Schuchter LM; Feldman MD; Ishwaran H; Vonderheide RH; Maity A; Wherry EJ; Minn AJ
Cell; 2016 Dec; 167(6):1540-1554.e12. PubMed ID: 27912061
[TBL] [Abstract][Full Text] [Related]
26. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
[TBL] [Abstract][Full Text] [Related]
27. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.
Ma Z; Li W; Yoshiya S; Xu Y; Hata M; El-Darawish Y; Markova T; Yamanishi K; Yamanishi H; Tahara H; Tanaka Y; Okamura H
Clin Cancer Res; 2016 Jun; 22(12):2969-80. PubMed ID: 26755531
[TBL] [Abstract][Full Text] [Related]
28. Targeting Immune Checkpoints in Cancer Therapy.
Topalian SL
JAMA; 2017 Nov; 318(17):1647-1648. PubMed ID: 28885639
[No Abstract] [Full Text] [Related]
29. Checkpoint blockade immunotherapy for cancer comes of age.
Brower V
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25745014
[No Abstract] [Full Text] [Related]
30. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
Buchbinder E; Hodi FS
J Clin Invest; 2015 Sep; 125(9):3377-83. PubMed ID: 26325034
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoints and their inhibition in cancer and infectious diseases.
Dyck L; Mills KHG
Eur J Immunol; 2017 May; 47(5):765-779. PubMed ID: 28393361
[TBL] [Abstract][Full Text] [Related]
32. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
33. Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier!
Castro MG; Baker GJ; Lowenstein PR
Clin Cancer Res; 2014 Oct; 20(20):5147-9. PubMed ID: 24879798
[TBL] [Abstract][Full Text] [Related]
34. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
[TBL] [Abstract][Full Text] [Related]
35. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.
Zarbo A; Belum VR; Sibaud V; Oudard S; Postow MA; Hsieh JJ; Motzer RJ; Busam KJ; Lacouture ME
Br J Dermatol; 2017 Jun; 176(6):1649-1652. PubMed ID: 27943234
[TBL] [Abstract][Full Text] [Related]
36. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
37. Cancer immunotherapy in patients with preexisting autoimmune disorders.
Donia M; Pedersen M; Svane IM
Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
[TBL] [Abstract][Full Text] [Related]
38. Checkpoint inhibitors: outstanding efficacy but at what cost?
Klastersky JA
Curr Opin Oncol; 2016 Jul; 28(4):253. PubMed ID: 27163724
[No Abstract] [Full Text] [Related]
39. Breakthrough of the year 2013. Cancer immunotherapy.
Couzin-Frankel J
Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284
[No Abstract] [Full Text] [Related]
40. Approvals in 2016: the march of the checkpoint inhibitors.
Blumenthal GM; Pazdur R
Nat Rev Clin Oncol; 2017 Feb; 14(3):131-132. PubMed ID: 28218255
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]